向的TLR9激动剂引起有效的抗瘤免疫力,对抗自发发生的乳腺瘤
Caitlyn L Miller1, Idit Sagiv-Barfi2, Patrick Neuhöfer3,4,5
1Department of Bioengineering, Stanford University, Stanford, CA.
Journal of immunology (Baltimore, Md. : 1950)
|May 31, 2023
概括
向的TLR9激动剂治疗有效地减少了小鼠的自发乳腺瘤. 这种免疫治疗方法刺激了全身免疫反应,创造了记忆,以防止新的瘤生长,并为癌症治疗提供了洞察力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 临床前癌症模型
背景情况:
- 基因工程小鼠的自发瘤为人类癌症提供了一个相关的模型,包括对免疫疗法的耐药性.
- 了解瘤免疫相互作用对于开发有效的癌症治疗非常重要.
研究的目的:
- 研究瘤向的托尔类受体9 (TLR9) 刺激如何重塑瘤微环境.
- 评估一种新型TLR9激动剂在自发性多部位乳腺癌模型中的疗效.
主要方法:
- 使用了具有自发异质乳腺瘤的MMTV-PyMT转基因小鼠.
- 静脉注射一种瘤向TLR9激动剂 (PIP-CpG).
- 进行了广泛的免疫分析,以分析瘤微环境和系统免疫的变化.
主要成果:
- PIP-CpG诱导了现有的乳腺瘤的回归,并建立了针对新出现的瘤的免疫记忆.
- 治疗强化了瘤微环境中的化学激素和细胞激素的产生.
- 观察到先天性和适应性免疫细胞的强烈透和扩张,免疫表型发生显著变化.
结论:
- 针对瘤的TLR9刺激可以在本土的多部位癌症模型中实现有效的全身治疗.
- 这种方法显示了促进抗瘤免疫力和克服免疫疗法耐药性的潜力.
- 这些发现为未来的癌症治疗策略提供了宝贵的免疫学见解.
相关概念视频
01:27Tumor Immunotherapy
577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K